Last reviewed · How we verify

Skin and Skin Structure Pseudomonas Aeruginosa Infection — Treatment Landscape & Competitive Intelligence

Skin and Skin Structure Pseudomonas Aeruginosa Infection (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Skin and Skin Structure Pseudomonas Aeruginosa Infection, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Cipro ciprofloxacin Bayer AG Fluoroquinolone antibiotic DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A 1987-10-22
Azactam AZTREONAM Bristol-Myers Squibb Monobactam Antibacterial [EPC] 1986-01-01
Fortaz Ceftazidime Pai Holdings Pharm Third-generation cephalosporin Bacterial cell wall 1985-01-01
Arikayce Kit AMIKACIN Bristol-Myers Squibb Aminoglycoside Antibacterial 1981-01-01
Vantobra Tobramycin Sulfate Pfizer tobramycin Taste receptor type 2 member 20 1974-01-01
Garamycin GENTAMICIN Merck & Co. Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 5 1970-01-01
Gentamicin Gentamicin Sulfate Merck & Co. gentamicin Dihydrofolate reductase 1970-01-01
Tobi tobramycin Novartis Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Ceftazidim Ceftazidim Tel-Aviv Sourasky Medical Center Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI
Ofloxacine Ofloxacine Assistance Publique - Hôpitaux de Paris Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 6 drugs in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  2. Merck & Co. · 2 drugs in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  3. Bristol-Myers Squibb · 2 drugs in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  4. Pai Holdings Pharm · 2 drugs in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  5. Pfizer · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  6. Poitiers University Hospital · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  7. Tel-Aviv Sourasky Medical Center · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  8. University Hospital, Lille · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  9. Assistance Publique - Hôpitaux de Paris · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  10. Bayer AG · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection
  11. Novartis · 1 drug in Skin and Skin Structure Pseudomonas Aeruginosa Infection

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Skin and Skin Structure Pseudomonas Aeruginosa Infection:

Cite this brief

Drug Landscape (2026). Skin and Skin Structure Pseudomonas Aeruginosa Infection — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/skin-and-skin-structure-pseudomonas-aeruginosa-infection. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing